
According to the CDC, individuals receiving meningococcal vaccines targeting meningococcal serogroups A, C, Y, and W-135 (Menactra or Menveo) may experience mild side effects such as pain or redness at...

In October 2023, the FDA approved use of PENBRAYA, a pentavalent meningococcal vaccine targeting the A, B, C, W, and Y meningococcal serogroups. According to the vaccine’s package insert, the...

Meningococcal serogroup B (MenB) vaccines received FDA approval based on blood tests indicating immune response (immunogenicity) to the particular strains found within the vaccine. Meningococcal serogroup B strains, however, are...

MenQuadfi received FDA approval 2020 based on clinical trials that reported the vaccine was not inferior in safety or immunogenicity when compared with Menomune, Menactra, and Menveo conjugate vaccines. ...

Approved by the FDA in 2010, Menveo (serogroups A, C, Y, and W-135) conjugate vaccine approval was based on safety and immunogenicity studies reporting the vaccine to be non-inferior to...

Clinical trials on Menactra’s (MCV4 or MenACWY-D) efficacy were not a requirement when FDA licensed its use in 2005. Menactra was the first meningococcal (serogroups A, C, Y, and W-135)...

Meningococcal vaccine recommendations are scheduled to be reviewed in the next 15 months. Potential changes to the meningococcal recommendations may potentially include the elimination of the age 11–12-year-old meningococcal vaccine...

On October 20, 2023, the FDA approved PENBRAYA, a meningococcal conjugate vaccine targeting meningococcal serogroups A, B, C, Y, and W-135. This vaccine was approved in individuals between the ages...

The first meningococcal serogroup B vaccine, TRUMENBA, manufactured by Wyeth (Pfizer) pharmaceuticals, received FDA approval for use in persons aged 10 through 25 years of age on October 29, 2014. ...

The first meningococcal conjugate vaccine, Menactra, manufactured by Sanofi Pasteur, received FDA approval in January 2005 for use in persons ages 11 through 55 years. Menactra (MCV4 or MenACWY-D), a...